Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11553069 | 0.98 | SIGMAR1 (0.48) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL3028982 | 0.98 | SIGMAR1 (0.48) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL18917615 | 0.98 | SIGMAR1 (0.48) | MAOAMAOBSIGMAR1L3MBTL1MAPT | |
| SCHEMBL3030818 | 0.96 | HTR2A (0.47) | MAOAMAOBSIGMAR1L3MBTL1HTR2A | |
| SCHEMBL2528409 | 0.89 | MAOA (0.31) | MAOAMAOB | |
| SCHEMBL158396 | 0.87 | MAOA (0.43) | MAOAMAOBSIGMAR1HTR2A | |
| SCHEMBL11863151 | 0.87 | SIGMAR1 (0.32) | MAOASIGMAR1MAPTRXFP1 | |
| SCHEMBL3450884 | 0.84 | HTR2A (0.30) | HTR2A | |
| SCHEMBL3021800 | 0.83 | SIGMAR1 (0.38) | MAOAMAOBSIGMAR1MAPTRXFP1 | |
| SCHEMBL8587042 | 0.82 | TDP1 (0.51) | SIGMAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716386-A | Novel exosome inhibitor and preparation method thereof | 北京和理咨询有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114716386-A | Novel exosome inhibitor and preparation method thereof | 北京和理咨询有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-107827875-B | Application of benzimidazole derivative as cyclin-dependent kinase 4/6 inhibitor | 文韬创新药物研究（北京）有限责任公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-110799508-A | Heterocyclic compound and organic light-emitting element comprising same | 株式会社LG化学 | 2020-02-14 | — | — | CN | disclosed |
| US-6914119-B2 | Heat-resistant polyether, curable polyether, and coating liquid for forming a polyether film | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-07-05 | — | — | US | disclosed |
| EP-1404325-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030060591-A1 | Heat-resistant polyether, curable polyether, and coating liquid for forming a polyether film | SUMITOMO CHEMICAL COMPANY, LIMITED | 2003-03-27 | — | — | US | disclosed |
| WO-2002096420-A2 | METHOD FOR TREATING NERVE INJURY CAUSED BY SURGERY | GUILFORD PHARMACEUTICALS INC. (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1233945-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL Holdings, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| WO-1999062488-A1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999062491-A1 | SMALL MOLECULE PIPECOLIC ACID DERIVATIVE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998055090-A1 | HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| US-5801197-A | PIPECOLIC ACID DERIVATIVES FOR NERVE REGENERATION | GPI NIL HOLDINGS, INC. (US) | 1998-09-01 | — | — | US | disclosed |
| EP-0859614-A1 | ROTAMASE ENZYME ACTIVITY INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-08-26 | — | — | EP | disclosed |
| WO-1997016190-A1 | ROTAMASE ENZYME ACTIVITY INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-05-09 | — | — | WO | disclosed |
| US-5516797-A | SUPPRESSING GRAFT REJECTION | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1996-05-14 | — | — | US | disclosed |
| US-5330993-A | Immunosuppressive compounds | VERTEX PHARMACEUTICALS, INC. (US) | 1994-07-19 | — | — | US | disclosed |
| US-4272627-A | ANALGESICS, ANTIEMETICS, ANTIPSYCHOTICS | HOFFMANN-LA ROCHE INC. (US) | 1981-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060591-A1 | Heat-resistant polyether, curable polyether, and coating liquid for forming a polyether film | HEATR1, HSP90AA1, HEATR6 | MAOA 4464/4885MAOB 4664/4885SIGMAR1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.